$AVGO

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

Analysts upgraded Broadcom (AVGO) to Outperform with a $490 target, Deere (DE) to Outperform with an $813 target, and Dell (DELL) to Outperform with a $625 target. Moderna (MRNA) was downgraded to Sell with an $81 target. Seaport Research initiated Buy ratings on Devon Energy (DVN), Permian Resources (PR), and Viper Energy (VNOM).

Original reporting
Published Sep 3, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More — source image
Decision brief

The 30-second read

$AVGOBullishLow
01

Why it matters

The upgrades and downgrades provide modest directional cues but lack fresh catalyst, limiting immediate trading impact.

02

Market read

A collection of rating changes across multiple sectors offers limited actionable insight; overall market impact is muted.

03

What to watch

No new fundamental catalysts; price targets rely on analyst optimism.

Relevance 5/10Novelty 3/10Timing: Thursday

Background

The article aggregates analyst rating changes and price targets released on Thursday, September 3, 2026.

Company-level read

Ticker impact

$AVGOBullishMedium confidence
Context

Broadcom was upgraded to Outperform with a $490 price target.

Expected impact

Modest upside over weeks.

Evidence & confidence

Upgrade suggests improved outlook but no new catalyst.

$DEBullishMedium confidence
Context

Deere & Company was raised to Outperform with an $813 target.

Expected impact

Modest upside.

Evidence & confidence

Analyst upgrade signals better expectations.

$DELLBullishMedium confidence
Context

Dell Technologies was upgraded to Outperform with a $625 target.

Expected impact

Limited upside.

Evidence & confidence

Upgrade reflects improved view but no immediate catalyst.

$MRNABearishMedium confidence
Context

Moderna was cut to Sell with an $81 target.

Expected impact

Potential decline toward target.

Evidence & confidence

Downgrade indicates weaker outlook.

$PCGNeutralMedium confidence
Context

PG&E was cut to Hold with a $17 target.

Expected impact

Flat to slightly lower.

Evidence & confidence

Hold rating suggests no strong move.

$RAREBearishMedium confidence
Context

Ultragenyx was downgraded to In Line with a $16 target.

Expected impact

Potential decline.

Evidence & confidence

Target cut reflects weaker expectations.

$DVNBullishMedium confidence
Context

Devon Energy was initiated with a Buy rating and $65 target.

Expected impact

Moderate upside.

Evidence & confidence

New buy initiation suggests favorable view.

$PRBullishMedium confidence
Context

Permian Resources was started with a Buy rating and $45 target.

Expected impact

Modest upside.

Evidence & confidence

Buy initiation indicates positive outlook.

Market effects

Broad upgrades in tech and energy may lift sector sentiment.

US market sentiment modestly positive on Thursday.

Limited; primarily US equity focus.

Counterpoint

Upgrades may be premature without fresh earnings data.

Key entities

  • Broadcom

    Technology semiconductor firm upgraded to Outperform.

  • Deere & Company

    Agricultural equipment maker upgraded to Outperform.

Related articles

$RAREHighAI 9/10

Ultragenyx agrees to sell voucher for US$210M

Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.

$AVGOHigh

Broadcom Secures $50 Billion Financing for AI Chip Development

Broadcom Inc. (AVGO) is securing $50 billion in financing for AI chip development with OpenAI. The funds, provided by lenders like Apollo Global Management and Blackstone Group, aim to support 20 gigawatts of computing power financing for AI developers by 2028. Broadcom's stock is currently undervalued according to GuruFocus, with a GF Value™ of $421.04 versus a current price of $376.51, indicating a 10.6% margin of safety.

$RAREMed

How Investors May Respond To Ultragenyx (RARE) EMA Review Starts

Ultragenyx Pharmaceutical (RARE) announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application for rebisufligene etisparvovec, a gene therapy for Sanfilippo syndrome Type A. This validation confirms the filing is complete for review but does not guarantee approval. The company reported a US$115 million loss in Q2 2025 and has a cash runway of less than one year.